Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan

Journal of Clinical Epidemiology

Volumn 67, Issue 10, 2014, Pages 1139-1149

  Wu, Vin Cent ^a   Hu, Ya Hui ^b   Wu, Che Hsiung ^b   Kao, Chih Chin ^c   Wang, Cheng Yi ^d   Yang, Wei Shen ^a   Lee, Hsiu Hao ^e   Chang, Yuan Shian ^f   Lin, Yen Hung ^a   Wang, Shuo Meng ^a   Chen, Likwang ^g   Wu, Kwan Dun ^h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CARDINAL TIEN HOSPITAL   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f Postal Hospital   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^h National Health Research Institutes ^*  (Taiwan)

Author keywords

Adjudication; Administrative data; Medical chart review; Mineralocorticoid receptor antagonist; Primary aldosteronism; Validation

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; PRESCRIPTION DRUG; RENIN;

ADULT; ARTICLE; CONTROLLED STUDY; DATA EXTRACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ESSENTIAL HYPERTENSION; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; ICD-9-CM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATIONAL HEALTH INSURANCE; OUTPATIENT CARE; PATIENT IDENTIFICATION; PRESCRIPTION; PRIMARY HYPERALDOSTERONISM; REIMBURSEMENT; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TAIWAN; AGED; ALGORITHM; HYPERALDOSTERONISM; MEDICAL RECORD; MIDDLE AGED; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ALGORITHMS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPERALDOSTERONISM; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICAL RECORDS; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REPRODUCIBILITY OF RESULTS; TAIWAN;

EID: 84908238093     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2014.05.012     Document Type: Article

References (31)

1. G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, and C. Ferri A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J Am Coll Cardiol 48 2006 2293 2300
2. X. Sang, Y. Jiang, W. Wang, L. Yan, J. Zhao, and Y. Peng Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China J Hypertens 31 2013 1465 1471
3. S. Douma, K. Petidis, M. Doumas, P. Papaefthimiou, A. Triantafyllou, and N. Kartali Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study Lancet 371 2008 1921 1926
4. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 2005 1243 1248
5. S. Savard, L. Amar, P.F. Plouin, and O. Steichen Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study Hypertension 62 2013 331 336
6. C.T. Chao, V.C. Wu, C.C. Kuo, Y.H. Lin, C.C. Chang, and S.J. Chueh Diagnosis and management of primary aldosteronism: an updated review Ann Med 45 2013 375 383
7. L. Chen, W. Yip, M.C. Chang, H.S. Lin, S.D. Lee, and Y.L. Chiu The effects of Taiwan's National Health Insurance on access and health status of the elderly Health Econ 16 3 2007 223 242
8. National Health Insurance Administration of Taiwan. Public information on healthcare in National Health Insurance. Available at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu-id=1023&WD-ID=1023&webdata-id=859. Accessed May 1, 2014.
9. V.C. Wu, C.Y. Wang, C.C. Shiao, C.H. Chang, H.Y. Huang, and T.M. Huang Increased risk of active tuberculosis following acute kidney injury: a nationwide, population-based study PLoS One 8 2013 e69556
10. W.J. Wang, C.T. Chao, Y.C. Huang, C.Y. Wang, C.H. Chang, and T.M. Huang The impact of acute kidney injury with temporary dialysis on the risk of fracture J Bone Miner Res 29 3 2014 676 684
11. T.S. Lai, C.Y. Wang, S.C. Pan, T.M. Huang, M.C. Lin, and C.F. Lai Risk of developing severe sepsis after acute kidney injury: a population-based cohort study Crit Care 17 2013 R231
12. C.L. Chen, L. Chen, and W.C. Yang The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs BMC Public Health 8 2008 118
13. H.M. Lu, L. Chen, J.D. Wang, M.C. Hung, M.S. Lin, and Y.H. Yan Outcomes of prolonged mechanic ventilation: a discrimination model based on longitudinal health insurance and death certificate data BMC Health Serv Res 12 2012 100
14. J.W. Funder, R.M. Carey, C. Fardella, C.E. Gomez-Sanchez, F. Mantero, and M. Stowasser Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab 93 2008 3266 3281
15. L.A. Sechi, M. Novello, R. Lapenna, S. Baroselli, E. Nadalini, and G.L. Colussi Long-term renal outcomes in patients with primary aldosteronism JAMA 295 2006 2638 2645
16. V.C. Wu, H.W. Chang, K.L. Liu, Y.H. Lin, S.C. Chueh, and W.C. Lin Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests Am J Hypertens 22 2009 821 827
17. C.C. Kuo, V.C. Wu, K.H. Huang, S.M. Wang, C.C. Chang, and C.C. Lu Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group) J Renin Angiotensin Aldosterone Syst 12 2011 348 357
18. V.C. Wu, C.T. Chao, C.C. Kuo, Y.H. Lin, S.C. Chueh, and K.D. Wu Diagnosis and management of primary aldosteronism Acta Nephrologica 26 2012 111 120
19. D.G. Manuel, L.C. Rosella, and T.A. Stukel Importance of accurately identifying disease in studies using electronic health records BMJ 341 2010 440 443
20. C.L. Cheng, Y.H. Kao, S.J. Lin, C.H. Lee, and M.L. Lai Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan Pharmacoepidemiol Drug Saf 20 2011 236 242
21. C.C. Lin, M.S. Lai, C.Y. Syu, S.C. Chang, and F.Y. Tseng Accuracy of diabetes diagnosis in health insurance claims data in Taiwan J Formos Med Assoc 104 2005 157 163
22. S. Schneeweiss, and J. Avorn A review of uses of health care utilization databases for epidemiologic research on therapeutics J Clin Epidemiol 58 2005 323 337
23. D.F. Eisenberg, G.W. Daniel, J.K. Jones, E.L. Goehring Jr., P.M. Wahl, and P. Winters Validation of a claims-based diagnostic code for Stevens-Johnson syndrome in a commercially insured population Pharmacoepidemiol Drug Saf 21 2012 760 764
24. C.C. Lai, C.Y. Wang, H.M. Lu, L. Chen, N.C. Teng, and Y.H. Yan Idiopathic pulmonary fibrosis in Taiwan - a population-based study Respir Med 106 11 2012 1566 1574
25. R. Mamtani, K. Haynes, B.S. Finkelman, F.I. Scott, and J.D. Lewis Distinguishing incident and prevalent diabetes in an electronic medical records database Pharmacoepidemiol Drug Saf 23 2014 111 118
26. L.M. Fishman, O. Kuchel, G.W. Liddle, A.M. Michelakis, R.D. Gordon, and W.T. Chick Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria JAMA 205 1968 497 502
27. J.W. Peabody, J. Luck, S. Jain, D. Bertenthal, and P. Glassman Assessing the accuracy of administrative data in health information systems Med Care 42 2004 1066 1072
28. D.B. Preen, C.D. Holman, D.M. Lawrence, N.J. Baynham, and J.B. Semmens Hospital chart review provided more accurate comorbidity information than data from a general practitioner survey or an administrative database J Clin Epidemiol 57 2004 1295 1304
29. Y. Ito, R. Takeda, S. Karashima, Y. Yamamoto, T. Yoneda, and Y. Takeda Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects Hypertens Res 34 2011 98 102
30. B.L. Strom Data validity issues in using claims data Pharmacoepidemiol Drug Saf 10 2001 389 392
31. M. Mockenhaupt, C. Viboud, A. Dunant, L. Naldi, S. Halevy, and J.N. Bouwes Bavinck Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study J Invest Dermatol 128 2008 35 44